By a News Reporter-Staff News Editor at Managed Care Weekly Digest -- Magellan Health, Inc. (NASDAQ:MGLN) announced that it has entered into an agreement to acquire Veridicus Holdings, LLC, a privately held pharmacy benefit management (PBM) organization with a unique set of clinical services and capabilities. Veridicus' differentiated approach to pharmacy management leverages proprietary analytics and clinical software that integrates pharmacy, medical and lab data to drive targeted interventions resulting in better health outcomes and lower costs for complex patient populations. In addition, Veridicus owns and operates a fully licensed insurance company which is contracted with the Centers for Medicare and Medicaid Services (CMS) and serves members enrolled in the Medicare Part D Employer Group Waiver Plan (EGWP) program (see also Medicare and Medicaid).
Headquartered in Salt Lake City and founded in 2006, Veridicus has approximately 130 employees. Veridicus serves a customer base with an underlying PBM membership of approximately 225,000 lives, the majority of which are under a long-term contract with a trust administering benefits for participating employers. Upon the closing of this acquisition, Doug Burgoyne, chief executive officer of Veridicus, and the Veridicus team will join Magellan Rx Management.
"As Magellan Rx Management continues to differentiate itself in the market by offering clinical management programs and a value-based approach, Veridicus' programs and expertise will be a welcome addition," said Barry M. Smith, chairman and chief executive officer of Magellan Health.
"I am pleased to welcome Veridicus and Doug Burgoyne to the Magellan Rx Management team," said Mostafa Kamal, chief executive officer of Magellan Rx Management. "This acquisition will build upon Magellan Rx Management's clinically oriented approach to PBM services with additional capabilities that further amplify our laser focus on improving quality of care and outcomes for the patients we serve, while reining in overall costs for payers. As we continue to solidify our position as a value-based PBM, this acquisition makes a great deal of strategic sense."
"Joining Magellan Rx Management right now is an exciting opportunity, and I'm pleased to be able to bring Veridicus' expertise to Magellan," said Burgoyne. "Our 10 years of experience, as well as our position as an industry leader in clinical care management on behalf of our commercial and Medicare Part D clients, will align well with Magellan Rx Management's vision and growth strategy."
The purchase price is $74.5 million to be paid at closing. Further details will be provided on Magellan Health's 2017 Guidance Call, to be held Tuesday, November 22, 2016.
Closing of the transaction is expected before the end of the year and is not subject to the Hart-Scott-Rodino Act. However, the transaction is subject to the approval of Utah state insurance regulators and other customary closing conditions.
Keywords for this news article include: Health Policy, Magellan Health Inc., Medicare and Medicaid.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC